Xie Shuwu, Male, an associate researcher, born in August 1978, a doctoral student of pharmacology of Fudan University and the vice director of reproductive pharmacological research group. Since 2007, he begins to work in Drug Development Section of the Shanghai Institute of Planned Parenthood Research (SIPPR) with research orientations covering contraception and birth control, infertility and new drugs against reproductive diseases. Now, he acts as a member of Chinese Pharmacological Society, the secretary general of Committee of Reproductive Pharmacology, Chinese Pharmacological Society, a government procurement expert of contraceptive medicine in the National Health and Family Planning Commission the Ministry of Finance of the People's Republic of China, as well as a review expert of the Natural Science Foundation of China. At present, he has published 10 SCI papers, applied for 5 patents and participated in writing some academic monographs such as Experimental Methodology of Pharmacology (Edition 4) and Report on Advances in Pharmacology, etc.. In addition to assuming 1 subject supported by the Natural Science Foundation of China and 1 subject by Natural Science Funds of Shanghai, he, as the backbone of relevant programs also took part in 3 projects supported by the “12th Five Year Plan” of the Ministry of Science and Technology, 1 key research and development plan of the “13th Five Year Plan” as well as other fund programs supported by National Health and Family Planning Commission, Science and Technology Commission of Shanghai Municipality, Shanghai Municipal Commission of Health and Family Planning and Shanghai Municipal Education Commission, etc.. Furthermore, he took part in developing two varieties of new drugs (Levonorgestrel Ethinylestradiol Contraceptive Patch and Compound Gestodene Patch), etc. that have obtained 2 clinical research approvals. In addition, animal models and cell models have been established by him in drug-inducing ways for reproductive diseases such as epididymis infertility, dysmenorrheal, abortion, gestation, hysteromyoma, endometriosis and ovarian cancer, etc.; combining molecular biology and molecular oncology, he cooperated with multiple domestically well-known pharmaceutical enterprises and research institutes to carry out new drug R & D, including Beijing Zizhu Pharmaceutical, Runbio Biotech Co., Ltd., Shanghai Institute of Materia Medica of Chinese Academy of Sciences, Second Military Medical University, and Shanghai Institute of Pharmaceutical Industry, etc.. research emphases have been exerted on a number of subjects, such as A Screening and Identification Study on Interference of New-type 5alpha Reductase Inhibitor on Epididymal Epididymal Cavity Fluid Protein After Blood-epididymis Barrier, A Study on Epididymis Infertility Caused by Icariin Intervention on Dutasteride Based on Epididymal Function and Gene Expression Regulating by Androgen, Preparation of Percutaneous Contraceptive Patch and R & D and Application of Traditional Chinese Anti-fertility Medicine, etc.